Rhumbline Advisers Emergent Bio Solutions Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q4 2024

A detailed history of Rhumbline Advisers transactions in Emergent Bio Solutions Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 10,239 shares of EBS stock, worth $47,713. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,239
Previous 12,250 16.42%
Holding current value
$47,713
Previous $102,000 4.9%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 30, 2025
SELL
$7.72 - $11.97 $15,524 - $24,071
-2,011 Reduced 16.42%
10,239 $97,000
Q3 2024

Nov 12, 2024
SELL
$5.72 - $14.77 $30,739 - $79,373
-5,374 Reduced 30.49%
12,250 $102,000
Q2 2024

Aug 01, 2024
SELL
$1.86 - $6.98 $130,051 - $488,041
-69,920 Reduced 79.87%
17,624 $120,000
Q1 2024

May 09, 2024
BUY
$1.5 - $3.41 $3,363 - $7,645
2,242 Added 2.63%
87,544 $221,000
Q4 2023

Feb 08, 2024
BUY
$1.82 - $3.16 $3,942 - $6,844
2,166 Added 2.61%
85,302 $204,000
Q3 2023

Nov 09, 2023
SELL
$3.17 - $7.91 $246,074 - $614,021
-77,626 Reduced 48.29%
83,136 $282,000
Q2 2023

Aug 08, 2023
BUY
$7.35 - $13.21 $17,684 - $31,783
2,406 Added 1.52%
160,762 $1.18 Million
Q1 2023

May 11, 2023
BUY
$7.79 - $16.29 $56,017 - $117,141
7,191 Added 4.76%
158,356 $1.64 Million
Q4 2022

Feb 14, 2023
BUY
$11.0 - $21.45 $4,829 - $9,416
439 Added 0.29%
151,165 $1.79 Million
Q3 2022

Nov 10, 2022
BUY
$20.09 - $35.8 $102,981 - $183,510
5,126 Added 3.52%
150,726 $3.16 Million
Q2 2022

Aug 11, 2022
BUY
$27.42 - $43.63 $80,450 - $128,010
2,934 Added 2.06%
145,600 $4.52 Million
Q1 2022

May 12, 2022
BUY
$36.48 - $52.22 $55,267 - $79,113
1,515 Added 1.07%
142,666 $5.86 Million
Q4 2021

Feb 10, 2022
SELL
$33.11 - $55.01 $259,979 - $431,938
-7,852 Reduced 5.27%
141,151 $6.14 Million
Q3 2021

Nov 12, 2021
BUY
$50.07 - $66.05 $216,953 - $286,194
4,333 Added 3.0%
149,003 $7.46 Million
Q2 2021

Aug 05, 2021
BUY
$56.61 - $80.46 $1.17 Million - $1.66 Million
20,617 Added 16.62%
144,670 $9.11 Million
Q1 2021

May 06, 2021
SELL
$86.23 - $125.19 $529,107 - $768,165
-6,136 Reduced 4.71%
124,053 $11.5 Million
Q4 2020

Feb 10, 2021
BUY
$79.17 - $111.47 $260,469 - $366,736
3,290 Added 2.59%
130,189 $11.7 Million
Q3 2020

Nov 12, 2020
SELL
$81.91 - $134.94 $1.07 Million - $1.76 Million
-13,013 Reduced 9.3%
126,899 $13.1 Million
Q2 2020

Aug 13, 2020
SELL
$54.33 - $89.52 $358,686 - $591,011
-6,602 Reduced 4.51%
139,912 $11.1 Million
Q1 2020

May 06, 2020
BUY
$49.34 - $68.76 $44,652 - $62,227
905 Added 0.62%
146,514 $8.48 Million
Q4 2019

Feb 05, 2020
BUY
$51.21 - $59.06 $451,774 - $521,027
8,822 Added 6.45%
145,609 $7.86 Million
Q3 2019

Oct 23, 2019
BUY
$40.6 - $57.2 $31,465 - $44,330
775 Added 0.57%
136,787 $7.15 Million
Q2 2019

Aug 14, 2019
BUY
$39.92 - $53.86 $164,709 - $222,226
4,126 Added 3.13%
136,012 $6.57 Million
Q1 2019

May 01, 2019
BUY
$48.23 - $66.16 $151,008 - $207,146
3,131 Added 2.43%
131,886 $6.66 Million
Q4 2018

Jan 31, 2019
BUY
$55.63 - $73.24 $1.35 Million - $1.78 Million
24,354 Added 23.33%
128,755 $7.63 Million
Q3 2018

Nov 07, 2018
BUY
$52.05 - $66.51 $460,330 - $588,214
8,844 Added 9.26%
104,401 $6.87 Million
Q2 2018

Aug 06, 2018
BUY
$48.33 - $55.64 $574,015 - $660,836
11,877 Added 14.19%
95,557 $4.83 Million
Q1 2018

May 02, 2018
BUY
$44.44 - $54.39 $64,526 - $78,974
1,452 Added 1.77%
83,680 $4.41 Million
Q4 2017

Feb 09, 2018
BUY
$37.77 - $47.75 $430,540 - $544,302
11,399 Added 16.09%
82,228 $3.82 Million
Q3 2017

Nov 06, 2017
BUY
$34.14 - $40.45 $2.42 Million - $2.87 Million
70,829
70,829 $2.87 Million

Others Institutions Holding EBS

# of Institutions
173
Shares Held
36.7M
Call Options Held
336K
Put Options Held
203K
View Full List

About Emergent BioSolutions Inc.

EBS Quotes by TradingView
  • Ticker EBS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 49,861,500
  • Market Cap $232M
  • Description
  • Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emergi...
More about EBS
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email